Here, in this study, we have further expanded on the utility of ScPGseq to understand the AML development and relapse in a single case of AML, that at presentation had been assigned to the ELN favorable‐risk group based on the presence of NPM1 mutation and the low FLT3‐ITD AR at presentation. This evidence concerns the gene FLT3 and acute myeloid leukemia.